MiNK Therapeutics, Inc. (INKT) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -26,721.73%, forward earnings yield 9.70%.
Criteria proven by this page:
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -12.1 | 0.00 | -7.95 | 418.96 | - |
| 2020 | -24.5 | 0.66 | -7.37 | 0.00 | - |
| 2021 | -4.9 | -0.06 | 6.28 | 0.00 | - |
| 2022 | -3.1 | 0.39 | -219.00 | 0.00 | - |
| 2023 | -1.6 | 0.08 | -2.04 | 0.00 | - |
| 2024 | -2.4 | 0.04 | -1.33 | 0.00 | - |
| 2025 | 0.0 | 0.00 | -3.35 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.78 | $689.63K | $-25.91M | -3757.7% |
| 2020 | $-0.47 | $0.00 | $-15.68M | - |
| 2021 | $-0.69 | $0.00 | $-23.11M | - |
| 2022 | $-0.74 | $2.7B | $-24.78M | -0.9% |
| 2023 | $-0.65 | $0.00 | $-22.46M | - |
| 2024 | $-285.82 | $0.00 | $-10.78M | - |
| 2025 | $-2.93 | $0.00 | $-12.49B | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.61 | $-3.61 – $-3.61 | $125K | $125K – $125K | 1 |
| 2027 | $-3.85 | $-3.85 – $-3.85 | $4.4M | $4.4M – $4.4M | 1 |
| 2028 | $-1.52 | $-2.42 – $-0.62 | $33M | $33M – $33M | 2 |
| 2029 | $0.49 | $0.49 – $0.49 | $62.4M | $62.4M – $62.4M | 1 |
| 2030 | $1.31 | $1.31 – $1.31 | $85M | $85M – $85M | 1 |
